Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia

View through CrossRef
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy. Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia. Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk. However, little systematic analysis has been conducted about comparison between these two drugs. Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia. Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)". Only studies with randomized controlled trials were included in the meta-analysis. We screened out a total number of seven clinical trials. This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.27, 95% confidence interval = 0.98 to 1.64, p = 0.07). We further divided the seven studies into two subgroups based on age and treatment time. The young group (age <= 19) showed no significant difference (OR = 1.10, p = 0.65). While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.44, p = 0.05). The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.40, p = 0.05). While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.06, p = 0.79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.47, I2=0%, and p-value = 0.96) in this meta-analysis. It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period. This meta-analysis is practically important during antibiotic treatment in FN management.
Title: A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia
Description:
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy.
Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia.
Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk.
However, little systematic analysis has been conducted about comparison between these two drugs.
Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia.
Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)".
Only studies with randomized controlled trials were included in the meta-analysis.
We screened out a total number of seven clinical trials.
This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.
27, 95% confidence interval = 0.
98 to 1.
64, p = 0.
07).
We further divided the seven studies into two subgroups based on age and treatment time.
The young group (age <= 19) showed no significant difference (OR = 1.
10, p = 0.
65).
While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.
44, p = 0.
05).
The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.
40, p = 0.
05).
While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.
06, p = 0.
79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.
47, I2=0%, and p-value = 0.
96) in this meta-analysis.
It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period.
This meta-analysis is practically important during antibiotic treatment in FN management.

Related Results

Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Tazobactam selects for multidrug resistance
Tazobactam selects for multidrug resistance
Abstract Piperacillin-Tazobactam is a β-lactam/β-lactamase inhibitor combination that is amongst the most prescribed antimicrobials in hospital medicine. Piperacillin is ...
Neurotoxic effects of a well known antibiotic!
Neurotoxic effects of a well known antibiotic!
To the Editor, Cefepime is a fourth-generation cephalosporin with broad-spectrum antimicrobial activity covering a wide range of both gram-negative and gram positive organisms. It ...
Tazobactam selects for multidrug resistance
Tazobactam selects for multidrug resistance
AbstractPiperacillin-Tazobactam is a β-lactam/β-lactamase inhibitor combination which is amongst the most prescribed antimicrobials in hospital medicine. Piperacillin is inactivate...
The prevalence of neutropenia in chemotherapy cancer patients at a provincial hospital, Thailand
The prevalence of neutropenia in chemotherapy cancer patients at a provincial hospital, Thailand
Abstract Introduction Cancer patients with neutropenia (&lt;1500 cell/mm3 absolute neutrophil count [ANC]) are at high risk ...
Hippocampal Concentrations Drive Seizures in a Rat Model for Cefepime-induced Neurotoxicity
Hippocampal Concentrations Drive Seizures in a Rat Model for Cefepime-induced Neurotoxicity
BackgroundIn high dose, cefepime causes neurotoxicity in patients with kidney injury; however, the relationship between exposure and observed neurotoxicity is not clear, and no ani...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...

Back to Top